LUAD

Personalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring

Retrieved on: 
Tuesday, March 26, 2024
Biotechnology, Genetics, Health, Oncology, WGS, Genomics, Plasma, Congress, PPM, PSNL, NSCLC, Adenocarcinoma, Patient, Publishing, DNA, Cancer, LUAD, Lung cancer, NeXT, Neoplasm, ESMO, MRD, Medicare, Recurrence, Medical imaging

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced a new publication validating the company’s NeXT Personal test, an ultra-sensitive, tumor-informed circulating tumor DNA (ctDNA) assay.

Key Points: 
  • Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced a new publication validating the company’s NeXT Personal test, an ultra-sensitive, tumor-informed circulating tumor DNA (ctDNA) assay.
  • “The robust validation results in this publication provide a foundational building block towards achieving Medicare coverage for NeXT Personal,” said Richard Chen, MD, MS, Chief Medical Officer and Executive Vice President, R&D of Personalis.
  • “Taken together, the results show NeXT Personal’s capability for ultra-sensitive detection of ctDNA in patient plasma samples and the test’s potential to reliably inform clinicians and patients on residual cancer, cancer treatment response, and cancer recurrence through ctDNA detection, earlier than conventional detection approaches,” Chen noted.
  • This data from the TRACERx Study demonstrated the assay was able to find cancer nearly a year ahead of imaging and was predictive of clinical outcomes in early-stage lung cancer patients.

Validation Data on a Novel Prognostic Test Developed by GRAIL in Stage I Lung Cancer Presented at North America Conference on Lung Cancer

Retrieved on: 
Wednesday, December 6, 2023
Pharmaceutical, Research, Insurance, Oncology, Medical Devices, Hospitals, Genetics, Data Management, Professional Services, Science, Technology, Clinical Trials, Managed Care, General Health, FDA, Biotechnology, Health, Health Technology, Lung, DNA, AstraZeneca, Neoplasm, Methylation, Plasma, LUAD, Risk, Patient, Circulating tumor DNA, Conference, MD, Cancer, Lung cancer, Adenocarcinoma, Medical imaging, GRAIL

This is a novel tissue-free diagnostic that has the potential to identify high-risk patients prior to surgery and/or treatment.

Key Points: 
  • This is a novel tissue-free diagnostic that has the potential to identify high-risk patients prior to surgery and/or treatment.
  • The findings were presented in poster sessions at the North America Conference on Lung Cancer 2023 in Chicago, held Dec. 1-3, 2023.
  • A GRAIL assay was used to measure ctDNA detection with a prespecified threshold in a prospectively defined retrospective study.
  • The presence of ctDNA correlated with an inferior two-year recurrence-free survival (HR 3.8 [95%CI 2.3–6.4], P

Analysis from TRACERx Study Reveals More Sensitive and Earlier ctDNA Detection in Lung Cancer Patients by Personalis' MRD Technology

Retrieved on: 
Saturday, October 21, 2023
Oncology, Health, Biometrics, Health Technology, Clinical Trials, Biotechnology, Patient, Francis Crick Institute, NSCLC, University College London, ESMO, Lung cancer, Congress, PPM, Publication, Professor, Adenocarcinoma, Fear, R, UCL, Death, LUAD, Risk, Recurrence, MRD, Risk assessment, CT, Blood, PSNL, European Society for Medical Oncology, NeXT, Cancer, Neoplasm, MS, DNA, Medical imaging, MD, Chief Justice of Hungary

(Nasdaq: PSNL), a leader in precision oncology, today announced the presentation of initial findings from its work with the groundbreaking TRACERx lung cancer study, marking a substantial advancement in lung cancer circulating tumor DNA (ctDNA) detection and management.

Key Points: 
  • (Nasdaq: PSNL), a leader in precision oncology, today announced the presentation of initial findings from its work with the groundbreaking TRACERx lung cancer study, marking a substantial advancement in lung cancer circulating tumor DNA (ctDNA) detection and management.
  • Lung cancer is the second most common cancer in the U.S., with an estimated 238,000 new cases and approximately 127,000 deaths forecasted for 2023.
  • For the current analysis, the teams used NeXT Personal to identify and track MRD in over 170 patients from the TRACERx cohort.
  • The study demonstrated that pre-surgical ctDNA levels with NeXT Personal could be used to classify early-stage lung cancer patients into lower- and higher-recurrence risk groups.

GeneCentric Therapeutics Announces Publication of New Results Showing Clinical Benefit of RNA-based Antifolate Predictive Response Signature (AF-PRS) to Guide Lung Cancer Treatment Selection

Retrieved on: 
Thursday, July 20, 2023
Research, Genetics, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Therapy, Progression-free survival, Antifolate, Lung cancer, American Association for Cancer Research, SOC, RNA, PFS, Patient, Investment, Medicine, LUAD, Pharmaceutical industry, Labcorp

The retrospective analysis was published in the peer-reviewed journal Clinical Cancer Research,1 a journal of the American Association for Cancer Research.

Key Points: 
  • The retrospective analysis was published in the peer-reviewed journal Clinical Cancer Research,1 a journal of the American Association for Cancer Research.
  • The initial analysis focused on non-squamous non-small cell lung cancer (NS-NSCLC) patients treated with standard-of-care (SOC) pemetrexed/platinum doublet chemotherapy.
  • Results showed over half (53%) of patients that were AF-PRS(+) had extended progression-free survival (PFS) versus those who were AF-PRS(-) (16.6 months vs. 6.6 months; P=0.025).
  • When examining clinical response to therapy, 79% of patients demonstrating a complete response were AF-PRS(+).

Personalis Announces Four Abstracts Accepted for Presentation at AACR Annual Meeting 2023

Retrieved on: 
Wednesday, March 22, 2023
Research, Hospitals, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, DNA, Circulating tumor DNA, AACR, PMHC cellular microarray, TMB, ICI, SIM, HLA, IO, University Medical Center, OS, Cancer, American Association for Cancer Research, ICB, NSCLC, Biomarker, Meta-analysis, Immunotherapy, PPV, PSNL, Whole genome sequencing, MRD, Plasma, University Medical Center Hamburg-Eppendorf, Portrait, UKE, Patient, Melanoma, SIB, Immune system, TME, DdPCR, Neoplasm, LUAD, Medical imaging, Chief Justice of Hungary

Personalis, Inc. (Nasdaq: PSNL) today announced it is presenting new research data as scientific posters at the American Association for Cancer Research (AACR) Annual Meeting 2023, which convenes from April 14-19, 2023 in Orlando, Florida.

Key Points: 
  • Personalis, Inc. (Nasdaq: PSNL) today announced it is presenting new research data as scientific posters at the American Association for Cancer Research (AACR) Annual Meeting 2023, which convenes from April 14-19, 2023 in Orlando, Florida.
  • Most ctDNA-based MRD detection methods leverage a limited genomic footprint, restricting detection sensitivity and thus their utility in many clinical settings.
  • Along with proprietary algorithms, this achieves high MRD sensitivity with a limit of detection of 1 ~ 3 parts per million.
  • Relapses in early-stage LUAD patients were associated with neoantigens with lower immunogenicity and an immunosuppressive tumor microenvironment (TME).

In Silico: From Knowledge Curation to Clinical Trial Simulation, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, January 11, 2023
Research, Knowledge, Hospital, Clinical trial, Acceleration, Harvard Medical School, LUAD, NSCLC, Nova, EGFR, CPO, Medical device

TORONTO, Jan. 11, 2023 /PRNewswire-PRWeb/ -- These past few years have marked the acceleration of the adoption of in silico techniques for more efficient and innovative clinical research. When embarking on a new R&D program, scientists face a strategic imperative to assemble the best and most relevant available data and insights.

Key Points: 
  • In this free webinar, learn about using a clinical trial simulation platform to generate auditable and reproducible digital evidence.
  • Attendees will learn about jinkō, Novadiscovery's in silico clinical trial simulation platform.
  • The featured speakers will discuss how jinkō is rethinking scientific literature review and can help refine criteria for patient eligibility in the next trial.
  • Join this webinar to learn more about using a clinical trial simulation platform to generate auditable and reproducible digital evidence.

GeneCentric Therapeutics Identifies RNA-Based Genomic Markers of Clinical Response in Lung Cancer

Retrieved on: 
Tuesday, December 21, 2021
Research, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Lung cancer, University, LabCorp, Therapy, RNA-Seq, Pembrolizumab, DNA, Technology, LinkedIn, Neoplasm, Exploration, University of Tennessee Health Science Center, Genomics, Biotechnology, Precision medicine, Lung, Population, NSCLC, RNA, Cancer, Patient, LUAD, Pharmaceutical industry, Medical imaging, the Piedmont Study, GeneCentric, THE PIEDMONT STUDY, GENECENTRIC

We founded GeneCentric over a decade ago to study the genomics of lung cancer using the deep insights that can be obtained through gene expression analysis, said Neil Hayes, M.D., GeneCentric co-founder and Director of the University of Tennessee Health Science Center for Cancer Research.

Key Points: 
  • We founded GeneCentric over a decade ago to study the genomics of lung cancer using the deep insights that can be obtained through gene expression analysis, said Neil Hayes, M.D., GeneCentric co-founder and Director of the University of Tennessee Health Science Center for Cancer Research.
  • While our work has expanded well beyond the lung, the actionable clinical and genomic datasets we have developed have led to multiple signatures and related prototype tests.
  • GeneCentric Therapeutics, Inc. is an RNA-based genomic solutions provider based in Durham, North Carolina.
  • GeneCentric commercializes its technology through strategic collaborations with pharmaceutical, biotechnology and diagnostics companies in applications throughout preclinical testing, clinical drug development and commercialization lifecycle phases.